About the Company
at tcr2 therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. we have developed a unique proprietary truc™ platform based on t cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete t cell receptor (tcr). our truc™ variants can reprogram the natural tcr complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. we have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe truc™-t cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic. the company was founded in 2015 by dr. patrick baeuerle and backed with a $44.5m series a financing led by mpm capital and f2 ventures. we have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of kendall square in cambridge, ma.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TCRR News
Tcr2 Therapeutics (NASDAQ: TCRR)
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the ...
Todd Foley's Net Worth
Todd Foley has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., iTeos Therapeutics, Inc., TriVascular ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Kintara Therapeutics Inc KTRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
ONTX Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Viking Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Plus Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...